Scipher Medicine believes patients with autoimmune diseases deserve a simple answer to their treatment plan using scientifically backed data. By applying network medicine to its platform, we are developing diagnostic tests to identify patients who will not respond to...
Technology to significantly improve outcomes for autoimmune disease patients by ensuring optimal therapy is prescribed from day one WALTHAM, MA – December 19, 2019—Scipher Medicine, developer of a molecular technology platform used to ensure patients are prescribed...
Scipher aims to improve drug response predictions by incorporating protein interaction networks in its gene expression analysis algorithms. To improve the accuracy of therapeutic response predictions, Scipher has incorporated protein-protein interaction map into its...
The Precision Medicine Era PharmaVoice outlines why now is a new era of healthcare driven by precision medicine and how we got here, including the new trends in research to how we are moving these advancements out of research onto the market. Multiple leaders in...
Shifting Precision Medicine from Oncology to Autoimmune Diseases The Bio Report featured a podcast about precision medicine in autoimmune diseases and spoke with Alif Saleh, CEO of Scipher, to learn more about how we use gene expression data, instead of DNA, to...
Feixiong Cheng1,2,3,4,5, István A. Kovács1,2 & Albert-László Barabási1,2,6,7 Drug combinations, offering increased therapeutic efficacy and reduced toxicity, play an important role in treating multiple complex diseases. Yet, our ability to identify and...
Boston Business Journal highlights local companies advancing healthcare using AI Artificial intelligence is changing healthcare from how we diagnose diseases, model drug development, and predict response to therapies. The Boston Business Journal names Scipher Medicine...
Scipher Medicine was featured in Technology Networks to discuss the power of RNA “Ineffective drugs have a profound impact on patients. First of all, the patient could be taking a medication that not only doesn’t make them feel better, but could also...
Published by GenomeWeb Scipher Medicine of Boston is hoping to develop molecular signatures that can predict a patient’s response to autoimmune disease drugs, pushing precision medicine into areas other than oncology. The company, which was founded in 2014 by...
Scipher Medicine Reports Positive Results for Prism, a Drug Response Test That Can Save the Health Insurance Industry $20 Billion by Avoiding Paying for Ineffective Therapies The blood test ensures patients with autoimmune diseases are prescribed the most effective...
Even though there are several different therapies with different mechanism of actions, 91% of patients are prescribed anti‑TNF therapy as first-line biologic DMARD treatment Published in The Journal of Precision Medicine Authors: Keith Johnson, PhD and Michael...
Keith Johnson, Nancy Schoenbrunner and Dina Ghiassian 2018 ACR/ARHP Annual Meeting Abstract: Background: Rheumatoid arthritis (RA) is a complex disease affecting about 1.3M adults in the US. The patient population is very heterogeneous; no single drug mechanism...
WALTHAM, Mass., Sept. 6, 2018 /PRNewswire/ — Scipher Medicine, developer of a molecular technology platform that can predict if a patient will actually respond to a particular drug therapy announced today that it has completed its Series A round led by...
Published in Nature: NJP Systems Biology and Applications Authors: Jörg Menche, Emre Guney, Amitabh Sharma, Patrick J. Branigan, Matthew J. Loza, Frédéric Baribaud, Radu Dobrin & Albert-László Barábasi npj Systems Biology...
Maksim Kitsak1,2, Amitabh Sharma1,2,3, Jörg Menche1,2,4,5, Emre Guney1,2,6, Susan Dina Ghiassian1,2,7, Joseph Loscalzo8 & Albert-László Barabási1,2,4,7,8,9 Genes carrying mutations associated with genetic diseases are present in all human cells; yet, clinical...
